

Glenn S. Kerner, Esq. (Attorney ID 043431987)  
Kate D. Seib, Esq. (Attorney ID 019702006)  
**GOODWIN PROCTER LLP**  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018-1405  
Tel: (212) 813-8800  
gkerner@goodwinprocter.com  
kseib@goodwinprocter.com

**FILED**

DEC 03 2013

Carol E. Hisee, P.J.Cv

George E. McDavid (Attorney ID 035581986)  
Shana E. Russo (Attorney ID 018902000)  
**REED SMITH LLP**  
Princeton Forrestal Village  
136 Main Street, Suite 250  
Princeton, New Jersey 08540  
Tel. (609) 987-0050  
gmcdavid@reedsmith.com  
srusso@reedsmith.com

*Attorneys for Defendants Teva Pharmaceuticals USA, Inc.,  
Barr Pharmaceuticals, LLC and Barr Laboratories, Inc.*

---

IN RE: FOSAMAX LITIGATION

:  
: SUPERIOR COURT OF NEW JERSEY  
: LAW DIVISION: ATLANTIC COUNTY  
:  
:  
: CIVIL ACTION  
:  
: CASE NO. 282  
:  
: MASTER DOCKET: ATL-L-3632-08

APPLIES TO ALL CASES

---

**CASE MANAGEMENT ORDER**

**THIS MATTER** having come before this Court by teleconference on November 18, 2013,  
and the parties having consented to the form and entry of this Order, and for good cause shown,

IT IS on this 3 day of December, 2013 **ORDERED** as follows:

1. On or before December 2, 2013, Plaintiffs' Liaison Counsel shall provide to Generic Defendants and this Court, a spreadsheet that identifies each plaintiff with claims currently pending against a generic defendant in this litigation and further provides: (1) each plaintiff's alleged dates of ingestion of alendronate, (2) the alleged manufacturer(s) of the alendronate ingested by each

plaintiff (including NDC codes identifying said manufacturer(s)), and (3) each plaintiff's alleged date of injury, in order to identify plaintiffs whose claims are subject to dismissal as to a generic defendant or generic defendants pursuant to this Court's October 2, 2013 Decision.

2. On or before December 18, 2013, Plaintiffs Liaison Counsel shall provide to Generic Defendants, for each plaintiff with claims currently pending against a generic defendant in this litigation, pharmacy records that support each plaintiff's alleged dates of ingestion of alendronate and the alleged manufacturer(s) of that alendronate.

3. In the event of an individual Plaintiff's failure to timely provide the information and pharmacy records set forth above, and in the absence of good cause shown for the delay, a named generic defendant may apply to the Court for dismissal of the individual matter without prejudice pursuant to R. 4:37-2(a).

4. This Case Management Order hereby amends and supersedes the May 3, 2013 Case Management Order with respect to deadlines for responsive pleadings as follows:

A. Any obligation of Generic Defendants to file responsive pleadings or otherwise move in response to the Complaints listed on Schedules A attached to all consent orders filed between January 18, 2013 and the date of this Order are hereby stayed until January 15, 2014.

B. Any obligation of Generic Defendants to file responsive pleadings or otherwise move in response to all other complaints in the above-captioned consolidated proceeding is hereby stayed until January 15, 2014. The cases subject to the stay shall not be procedurally dismissed pursuant to R. 1:13-7.

  
\_\_\_\_\_  
Carol E. Higbee P.J. Cv.